Moleculin Biotech’s WP1122 Receives Fast Track Status for Glioblastoma

Moleculin Biotech’s WP1122 has gained Fast Track status from the FDA for the treatment of glioblastoma multiforme, an aggressive cancer that occurs in the brain or spine.

WP1122 is a patented prodrug — an inactive compound that is metabolized in the body to produce a drug — that directs cells to pull in glucose from the blood.

In preclinical studies, WP1122 outperformed the standard of care in mice who were transplanted with human brain tumors, the company said.

WP1122 previously gained Orphan Drug status and FDA clearance for an Investigational New Drug application to begin a phase 1 clinical trial.